- Home
- KNSA vs CNTA Comparison
KNSA vs CNTA Comparison
Compare KNSA & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- CNTA
- Stock Information
- Founded
- KNSA 2015
- CNTA 2020
- Country
- KNSA United Kingdom
- CNTA United Kingdom
- Employees
- KNSA N/A
- CNTA N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- KNSA Health Care
- CNTA Health Care
- Exchange
- KNSA Nasdaq
- CNTA Nasdaq
- Market Cap
- KNSA 1.7B
- CNTA 2.0B
- IPO Year
- KNSA 2018
- CNTA 2021
- Fundamental
- Price
- KNSA $26.79
- CNTA $15.46
- Analyst Decision
- KNSA Strong Buy
- CNTA Strong Buy
- Analyst Count
- KNSA 5
- CNTA 7
- Target Price
- KNSA $33.60
- CNTA $23.14
- AVG Volume (30 Days)
- KNSA 283.3K
- CNTA 413.4K
- Earning Date
- KNSA 10-29-2024
- CNTA 11-11-2024
- Dividend Yield
- KNSA N/A
- CNTA N/A
- EPS Growth
- KNSA N/A
- CNTA N/A
- EPS
- KNSA N/A
- CNTA N/A
- Revenue
- KNSA $338,930,000.00
- CNTA $6,853,000.00
- Revenue This Year
- KNSA $58.95
- CNTA N/A
- Revenue Next Year
- KNSA $36.22
- CNTA N/A
- P/E Ratio
- KNSA N/A
- CNTA N/A
- Revenue Growth
- KNSA 20.69
- CNTA N/A
- 52 Week Low
- KNSA $14.12
- CNTA $5.58
- 52 Week High
- KNSA $27.92
- CNTA $17.59
- Technical
- Relative Strength Index (RSI)
- KNSA 58.67
- CNTA 48.83
- Support Level
- KNSA $23.33
- CNTA $15.51
- Resistance Level
- KNSA $27.35
- CNTA $16.47
- Average True Range (ATR)
- KNSA 0.89
- CNTA 0.75
- MACD
- KNSA 0.15
- CNTA -0.15
- Stochastic Oscillator
- KNSA 86.07
- CNTA 13.68
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.